Apoptosis is a cell suicide program that plays a critical role in development and tissue homeostasis. The ability of cancer cells to evade this programmed cell death (PCD) is a major characteristic that enables their uncontrolled growth. The efficiency of chemotherapy in killing such cells depends on the successful induction of apoptosis, since defects in apoptosis signaling are a major cause of drug resistance. Over the past decades, much progress has been made in our understanding of apoptotic signaling pathways and their dysregulation in cancer progression and therapy. These advances have provided new molecular targets for proapoptotic cancer therapies that have recently been used in drug development. While most of those therapies are still at the preclinical stage, some of them have shown much promise in the clinic. Here, we review our current knowledge of apoptosis regulation in cancer progression and therapy, as well as the new molecular targeted molecules that are being developed to reinstate cancer cell death.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2, 811–814.
Abe, K., Kurakin, A., Mohseni-Maybodi, M., Kay, B., and Khosravi-Far, R. (2000a). The complexity of TNF-related apoptosis-inducing ligand. Ann NY Acad Sci, 926, 52–63.
Abe, K., Kurakin, A., Mohseni-Maybodi, M., Kay, B., and Khosravi-Far, R. (2000b). The complexity of TNF-related apoptosis-inducing ligand. Ann N Y Acad Sci 926, 52–63.
Adams, J. (2003). The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29 (Suppl 1), 3–9.
Adams, J. (2004). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4, 349–360.
Adams, J. and Kauffman, M. (2004). Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 22, 304–311.
Adams, J. M. and Cory, S. (2002). Apoptosomes: engines for caspase activation. Curr Opin Cell Biol 14, 715–720.
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., and Brinster, R. L. (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533–538.
Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., et al. (2005). Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105, 3303–3311.
Algeciras-Schimnich, A., Shen, L., Barnhart, B. C., Murmann, A. E., Burkhardt, J. K., and Peter, M. E. (2002). Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 22, 207–220.
Alitalo, K. and Schwab, M. (1986). Oncogene amplification in tumor cells. Advances in Cancer Research 47, 235–281.
Almasan, A. and Ashkenazi, A. (2003). Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14, 337–348.
Amantana, A., London, C. A., Iversen, P. L., and Devi, G. R. (2004). X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3, 699–707.
Amundson, S. A., Myers, T. G., Scudiero, D., Kitada, S., Reed, J. C., and Fornace, A. J., Jr. (2000). An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 60, 6101–6110.
Appels, N. M., Beijnen, J. H., and Schellens, J. H. (2005). Development of farnesyl transferase inhibitors: a review. Oncologist 10, 565–578.
Arlt, A. and Schafer, H. (2002). NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 40, 336–347.
Arvanitis, C. and Felsher, D. W. (2006). Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 16, 313–317.
Ashkenazi, A. and Dixit, V. M. (1998). Death receptors: signaling and modulation. Science 281, 1305–1308.
Ashkenazi, A. and Dixit, V. M. (1999). Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11, 255–260.
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104, 155–162.
Baldwin, A. S. (2001). Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107, 241–246.
Baliga, B. and Kumar, S. (2003). Apaf-1/cytochrome c apoptosome: an essential initiator of caspase activation or just a sideshow? Cell Death Differ 10, 16–18.
Banerji, U., O’Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005). Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23, 4152–4161.
Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J., and Jones, R. J. (1994). Inhibition of apoptosis by Bcr-Abl in chronic myeloid leukemia. Blood 83, 2038–2044.
Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D. S., Sawyers, C. L., Arber, D. A., Slovak, M. L., and Forman, S. J. (2003). Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701–4707 (epub 2003 Feb 4706).
Bissonnette, R. P., Echeverri, F., Mahboubi, A., and Green, D. R. (1992). Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359, 552–554.
Blagosklonny, M. V. (2001). Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? Bioessays 23, 947–953.
Blagosklonny, M. V. (2002). P53: an ubiquitous target of anticancer drugs. Int J Cancer 98, 161–166.
Blume-Jensen, P. and Hunter, T. (2001). Oncogenic kinase signalling. Nature 411, 355–365.
Boatright, K. M., Renatus, M., Scott, F. L., Sperandio, S., Shin, H., Pedersen, I. M., Ricci, J. E., Edris, W. A., Sutherlin, D. P., Green, D. R., and Salvesen, G. S. (2003). A unified model for apical caspase activation. Mol Cell 11, 529–541.
Bouchier-Hayes, L., Lartigue, L., and Newmeyer, D. D. (2005). Mitochondria: pharmacological manipulation of cell death. J Clin Invest 115, 2640–2647.
Bouillet, P., Huang, D. C., O’Reilly, L. A., Puthalakath, H., O’Connor, L., Cory, S., Adams, J. M., and Strasser, A. (2000). The role of the pro-apoptotic Bcl-2 family member bim in physiological cell death. Ann N Y Acad Sci 926, 83–89.
Boxer, R. B., Jang, J. W., Sintasath, L., and Chodosh, L. A. (2004). Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6, 577–586.
Broker, L. E., Huisman, C., Span, S. W., Rodriguez, J. A., Kruyt, F. A., and Giaccone, G. (2004). Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 64, 27–30.
Bucur, O., Ray, S., Bucur, M. C., and Almasan, A. (2006). APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 11, 1549–1568.
Burns, T. F. and el-Deiry, W. S. (2003). Cell death signaling in maligancy. Cancer Treat Res 115, 319–343.
Bursch, W., Ellinger, A., Kienzl, H., Torok, L., Pandey, S., Sikorska, M., Walker, R., and Hermann, R. S. (1996). Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 17, 1595–1607.
Bykov, V. J., Selivanova, G., and Wiman, K. G. (2003). Small molecules that reactivate mutant p53. Eur J Cancer 39, 1828–1834.
Cain, K., Bratton, S. B., and Cohen, G. M. (2002). The Apaf-1 apoptosome: a large caspase-activating complex. Biochimie 84, 203–214.
Calvisi, D. F., Ladu, S., Factor, V. M., and Thorgeirsson, S. S. (2004). Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital. Carcinogenesis 25, 901–908.
Carlesso, N., Frank, D. A., and Griffin, J. D. (1996). Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183, 811–820.
Carlesso, N., Griffin, J. D., and Druker, B. J. (1994). Use of a temperature-sensitive mutant to define the biological effects of the p210Bcr-Abl tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 9, 149–156.
Chevallier, P., Robillard, N., Wuilleme-Toumi, S., Mechinaud, F., Harousseau, J. L., and Avet-Loiseau, H. (2004). Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. Haematologica 89, 1399–1401.
Chinnaiyan, A. M. (1999). The apoptosome: heart and soul of the cell death machine. Neoplasia 1, 5–15.
Chuang, S. E., Yeh, P. Y., Lu, Y. S., Lai, G. M., Liao, C. M., Gao, M., and Cheng, A. L. (2002). Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 63, 1709–1716.
Cohen, G. M. (1997). Caspases: the executioners of apoptosis. Biochem J 326 (Pt 1), 1–16.
Cortez, D., Stoica, G., Pierce, J. H., and Pendergast, A. M. (1996). The Bcr-Abl tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 13, 2589–2594.
Cory, S. and Adams, J. M. (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2, 647–656.
Costantini, P., Jacotot, E., Decaudin, D., and Kroemer, G. (2000). Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 92, 1042–1053.
Croxton, R., Ma, Y., Song, L., Haura, E. B., and Cress, W. D. (2002). Direct repression of the Mcl-1 promoter by E2F1. Oncogene 21, 1359–1369.
D’Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., Cox, J. D., Ha, S. I., Belka, G. K., Golant, A., et al. (2001). c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nature Medicine 7, 235–239.
Dagher, R., Cohen, M., Williams, G., Rothmann, M., Gobburu, J., Robbie, G., Rahman, A., Chen, G., Staten, A., Griebel, D., and Pazdur, R. (2002). Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8, 3034–3038.
Dang, C. V. (1999). c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19, 1–11.
Daniel, P. T., Wieder, T., Sturm, I., and Schulze-Osthoff, K. (2001). The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 15, 1022–1032.
De Marinis, F., De Santis, S., and De Petris, L. (2006). Second-line chemotherapy for non-small cell lung cancer. Ann Oncol 17 (Suppl 5), v68–v71.
Debatin, K. M. and Krammer, P. H. (2004). Death receptors in chemotherapy and cancer. Oncogene 23, 2950–2966.
Debatin, K. M., Poncet, D., and Kroemer, G. (2002). Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21, 8786–8803.
Degli Esposti, M. (1999). To die or not to die–the quest of the TRAIL receptors. J Leukoc Biol 65, 535–542.
Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T., and Yuan, J. (2001). Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3, 173–182.
Deininger, M., Buchdunger, E., and Druker, B. J. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640–2653 (epub 2004 Dec 2623).
Demoy, M., Minko, T., Kopeckova, P., and Kopecek, J. (2000). Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release 69, 185–196.
Dempke, W., Voigt, W., Grothey, A., Hill, B. T., and Schmoll, H. J. (2000). Cisplatin resistance and oncogenes–a review. Anticancer Drugs 11, 225–236.
Devarajan, E., Sahin, A. A., Chen, J. S., Krishnamurthy, R. R., Aggarwal, N., Brun, A. M., Sapino, A., Zhang, F., Sharma, D., Yang, X. H., et al. (2002). Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 21, 8843–8851.
Dias, N. and Bailly, C. (2005). Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol 70, 1–12.
Dole, M., Nunez, G., Merchant, A. K., Maybaum, J., Rode, C. K., Bloch, C. A., and Castle, V. P. (1994). Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54, 3253–3259.
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2, 561–566.
Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M., Arbuck, S. G., Travis, R., Sausville, E. A., and Houghton, P. J. (2001). Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7, 1758–1764.
Egan, L. J., Eckmann, L., Greten, F. R., Chae, S., Li, Z. W., Myhre, G. M., Robine, S., Karin, M., and Kagnoff, M. F. (2004). IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 101, 2452–2457.
Emanuel, P. D., Bates, L. J., Castleberry, R. P., Gualtieri, R. J., and Zuckerman, K. S. (1991). Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77, 925–929.
Emens, L. A. (2005). Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 12, 243–253.
Eng, C. P., Sehgal, S. N., and Vezina, C. (1984). Activity of rapamycin (AY-22, 989) against transplanted tumors. J Antibiot (Tokyo) 37, 1231–1237.
Enyedy, I. J., Ling, Y., Nacro, K., Tomita, Y., Wu, X., Cao, Y., Guo, R., Li, B., Zhu, X., Huang, Y., et al. (2001). Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 44, 4313–4324.
Erster, S. and Moll, U. M. (2005). Stress-induced p53 runs a transcription-independent death program. Biochem Biophys Res Commun 331, 843–850.
Esposti, M. D., Cristea, I. M., Gaskell, S. J., Nakao, Y., and Dive, C. (2003). Proapoptotic Bid binds to monolysocardiolipin, a new molecular connection between mitochondrial membranes and cell death. Cell Death Differ 10, 1300–1309.
Evan, G. I. and Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342–348.
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119–128.
Fan, J., Banerjee, D., Stambrook, P. J., and Bertino, J. R. (1997). Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras. Biochem Pharmacol 53, 1203–1209.
Fanidi, A., Harrington, E. A., and Evan, G. I. (1992). Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359, 554–556.
Felsher, D. W. and Bishop, J. M. (1999). Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA 96, 3940–3944.
Fernandez, P. C., Frank, S. R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A., and Amati, B. (2003). Genomic targets of the human c-Myc protein. Genes Dev 17, 1115–1129.
Fesik, S. W. (2005). Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5, 876–885.
Finnberg, N. and El-Deiry, W. S. (2004). Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther. 3, 614–616 (epub 2004 July 2024).
Foster, B. A., Coffey, H. A., Morin, M. J., and Rastinejad, F. (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510.
Friesen, C., Fulda, S., and Debatin, K. M. (1997). Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 11, 1833–1841.
Fujita, T., Washio, K., Takabatake, D., Takahashi, H., Yoshitomi, S., Tsukuda, K., Ishibe, Y., Ogasawara, Y., Doihara, H., and Shimizu, N. (2005). Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int. J Cancer 117, 670–682.
Fulda, S. and Debatin, K. M. (2000). Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med Pediatr Oncol 35, 616–618.
Fulda, S., Friesen, C., and Debatin, K. M. (1998a). Molecular determinants of apoptosis induced by cytotoxic drugs. Klin Padiatr 210, 148–152.
Fulda, S., Los, M., Friesen, C., and Debatin, K. M. (1998b). Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 76, 105–114.
Fulda, S., Kufer, M. U., Meyer, E., van Valen, F., Dockhorn-Dworniczak, B., and Debatin, K. M. (2001a). Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20, 5865–5877.
Fulda, S., Meyer, E., Friesen, C., Susin, S. A., Kroemer, G., and Debatin, K. M. (2001b). Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 20, 1063–1075.
Fulda, S., Wick, W., Weller, M., and Debatin, K. M. (2002). Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8, 808–815 (epub 2002 July 2015).
Furukawa, Y., Nishimura, N., Satoh, M., Endo, H., Iwase, S., Yamada, H., Matsuda, M., Kano, Y., and Nakamura, M. (2002). Apaf-1 is a mediator of E2F–1-induced apoptosis. J Biol Chem 277, 39760–39768 (epub 32002 July 39730).
Gambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., et al. (1997). Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis. Blood Cells Mol Dis 23, 380–394.
Gesbert, F. and Griffin, J. D. (2000). Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 96, 2269–2276.
Geske, F. J. and Gerschenson, L. E. (2001). The biology of apoptosis. Hum Pathol 32, 1029–1038.
Ghaffari, S., Jagani, Z., Kitidis, C., Lodish, H. F., and Khosravi-Far, R. (2003). Cytokines and Bcr-Abl mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci USA 100, 6523–6528.
Gilley, J., Coffer, P. J., and Ham, J. (2003). FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162, 613–622.
Giodini, A., Kallio, M. J., Wall, N. R., Gorbsky, G. J., Tognin, S., Marchisio, P. C., Symons, M., and Altieri, D. C. (2002). Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62, 2462–2467.
Gonda, T. J., Sheiness, D. K., and Bishop, J. M. (1982). Transcripts from the cellular homologs of retroviral oncogenes: distribution among chicken tissues. Mol Cell Biol 2, 617–624.
Gong, B. and Almasan, A. (2000). Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 278, 747–752.
Gourdier, I., Del Rio, M., Crabbe, L., Candeil, L., Copois, V., Ychou, M., Auffray, C., Martineau, P., Mechti, N., Pommier, Y., and Pau, B. (2002). Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529, 232–236.
Gozuacik, D. and Kimchi, A. (2004). Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23, 2891–2906.
Green, D. R. and Evan, G. I. (2002). A matter of life and death. Cancer Cell 1, 19–30.
Green, D. R. and Kroemer, G. (2004). The pathophysiology of mitochondrial cell death. Science 305, 626–629.
Gross, A., Yin, X. M., Wang, K., Wei, M. C., Jockel, J., Milliman, C., Erdjument-Bromage, H., Tempst, P., and Korsmeyer, S. J. (1999). Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274, 1156–1163.
Gudas, J. M., Nguyen, H., Li, T., Sadzewicz, L., Robey, R., Wosikowski, K., and Cowan, K. H. (1996). Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein. Carcinogenesis 17, 1417–1427.
Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57–70.
Harada, T., Ogura, S., Yamazaki, K., Kinoshita, I., Itoh, T., Isobe, H., Yamashiro, K., Dosaka-Akita, H. and Nishimura, M. (2003). Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 94, 394–399.
Harris, A. W., Pinkert, C. A., Crawford, M., Langdon, W. Y., Brinster, R. L., and Adams, J. M. (1988). The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 167, 353–371.
Heath, E. I., Gaskins, M., Pitot, H. C., Pili, R., Tan, W., Marschke, R., Liu, G., Hillman, D., Sarkar, F., Sheng, S., et al. (2005). A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 4, 138–141.
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., and Mills, G. B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4, 988–1004.
Herr, I. and Debatin, K. M. (2001). Cellular stress response and apoptosis in cancer therapy. Blood 98, 2603–2614.
Hickman, J. A. (2002). Apoptosis and tumourigenesis. Curr Opin Genet Dev 12, 67–72.
Hill, M. M., Adrain, C., and Martin, S. J. (2003). Portrait of a killer: the mitochondrial apoptosome emerges from the shadows. Mol Interv 3, 19–26.
Hirsimaki, Y. and Hirsimaki, P. (1984). Vinblastine-induced autophagocytosis: the effect of disorganization of microfilaments by cytochalasin B. Exp Mol Pathol 40, 61–69.
Horvitz, H. R. (1999). Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cancer Res 59, 1701s–1706s.
Hu, M. C., Lee, D. F., Xia, W., Golfman, L. S., Ou-Yang, F., Yang, J. Y., Zou, Y., Bao, S., Hanada, N., Saso, H., et al. (2004). IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225–237.
Huang, Y., Lu, M., and Wu, H. (2004). Antagonizing XIAP-mediated caspase-3 inhibition. Achilles’ heel of cancers? Cancer Cell 5, 1–2.
Hutchinson, J. N. and Muller, W. J. (2000). Transgenic mouse models of human breast cancer. Oncogene 19, 6130–6137.
Ilaria, R. L., Jr. and Van Etten, R. A. (1996). P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271, 31704–31710.
Ingvarsson, S. (1990). The myc gene family proteins and their role in transformation and differentiation. Semin Cancer Biol 1, 359–369.
Ionov, Y., Yamamoto, H., Krajewski, S., Reed, J. C., and Perucho, M. (2000). Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 97, 10872–10877.
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., and Kaelin, W. G., Jr. (2003). Chemosensitivity linked to p73 function. Cancer Cell 3, 403–410.
Jansen, B., Schlagbauer-Wadl, H., Eichler, H. G., Wolff, K., van Elsas, A., Schrier, P. I., and Pehamberger, H. (1997). Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 57, 362–365.
Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K., and Pehamberger, H. (2000). Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728–1733.
Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153–164.
Kabarowski, J. H., Allen, P. B., and Wiedemann, L. M. (1994). A temperature sensitive p210 Bcr-Abl mutant defines the primary consequences of Bcr-Abl tyrosine kinase expression in growth factor dependent cells. EMBO J 13, 5887–5895.
Kagawa, S., Gu, J., Swisher, S. G., Ji, L., Roth, J. A., Lai, D., Stephens, L. C., and Fang, B. (2000). Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res 60, 1157–1161.
Kaliberov, S. A., Buchsbaum, D. J., Gillespie, G. Y., Curiel, D. T., Arafat, W. O., Carpenter, M., and Stackhouse, M. A. (2002). Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol Ther 6, 190–198.
Kamesaki, S., Kamesaki, H., Jorgensen, T. J., Tanizawa, A., Pommier, Y., and Cossman, J. (1993). bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53, 4251–4256.
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., and Kondo, S. (2004). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11, 448–457.
Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., and Green, D. R. (1998). DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1, 543–551.
Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., Clardy, J., Sellers, W. R., and Silver, P. A. (2003). A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer cell 4, 463–476.
Kaufmann, S. H. and Earnshaw, W. C. (2000). Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256, 42–49.
Keeshan, K., Mills, K. I., Cotter, T. G., and McKenna, S. L. (2001). Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 15, 1823–1833.
Kelly, W. K., O’Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23, 3923–3931 (epub 2005 May 3916).
Khosravi-Far, R., Campbell, S., Rossman, K. L., and Der, C. J. (1998). Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv Cancer Res 72, 57–107.
Khosravi-Far, R. and Der, C. J. (1994). The Ras signal transduction pathway. Cancer Metastasis Rev 13, 67–89.
Kim, D., Dan, H. C., Park, S., Yang, L., Liu, Q., Kaneko, S., Ning, J., He, L., Yang, H., Sun, M., et al. (2005). AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 10, 975–987 (print 2005 Jan 2001).
Kim, R., Emi, M., Tanabe, K., and Toge, T. (2004). Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101, 2491–2502.
Kim, R., Emi, M., Tanabe, K., Uchida, Y., and Arihiro, K. (2006). The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur J Surg Oncol 20, 20.
Kim, R., Tanabe, K., Emi, M., Uchida, Y., Inoue, H., and Toge, T. (2003). Inducing cancer cell death by targeting transcription factors. Anticancer Drugs 14, 3–11.
Kirkin, V., Joos, S., and Zornig, M. (2004). The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644, 229–249.
Klasa, R. J., Gillum, A. M., Klem, R. E., and Frankel, S. R. (2002). Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12, 193–213.
Knies-Bamforth, U. E., Fox, S. B., Poulsom, R., Evan, G. I., and Harris, A. L. (2004). c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res 64, 6563–6570.
Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J., and Fan, Z. (2003). HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22, 3205–3212.
Kondo, Y., Kanzawa, T., Sawaya, R., and Kondo, S. (2005). The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5, 726–734.
Kostanova-Poliakova, D. and Sabova, L. (2005). Anti-apoptotic proteins-targets for chemosensitization of tumor cells and cancer treatment. Neoplasma 52, 441–449.
Koturbash, I., Rugo, R. E., Hendricks, C. A., Loree, J., Thibault, B., Kutanzi, K., Pogribny, I., Yanch, J. C., Engelward, B. P., and Kovalchuk, O. (2006). Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo. Oncogene 25, 4267–4275.
Kroemer, G. (2003). Mitochondrial control of apoptosis: an introduction. Biochem Biophys Res Commun 304, 433–435.
Kutzki, O., Park, H. S., Ernst, J. T., Orner, B. P., Yin, H., and Hamilton, A. D. (2002). Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc 124, 11838–11839.
Kuwana, T., Mackey, M. R., Perkins, G., Ellisman, M. H., Latterich, M., Schneiter, R., Green, D. R., and Newmeyer, D. D. (2002). Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111, 331–342.
Lawen, A. (2003). Apoptosis-an introduction. Bioessays 25, 888–896.
le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., and Gambacorti-Passerini, C. (1999). In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91, 163–168.
Letai, A., Sorcinelli, M. D., Beard, C., and Korsmeyer, S. J. (2004). Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6, 241–249.
Levine, A. J., Finlay, C. A., and Hinds, P. W. (2004). P53 is a tumor suppressor gene. Cell 116, S67–S69, 61 p following S69.
Levy, E., Baroche, C., Barret, J. M., Alapetite, C., Salles, B., Averbeck, D., and Moustacchi, E. (1994). Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair. Carcinogenesis 15, 845–850.
Li, H. and Yuan, J. (1999). Deciphering the pathways of life and death. Curr Opin Cell Biol 11, 261–266.
Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491–501.
Lima, R. T., Martins, L. M., Guimaraes, J. E., Sambade, C., and Vasconcelos, M. H. (2004). Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11, 309–316.
Lin, W. C., Lin, F. T., and Nevins, J. R. (2001). Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 15, 1833–1844.
Longley, D. B. and Johnston, P. G. (2005). Molecular mechanisms of drug resistance. J Pathol 205, 275–292.
Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., and Johnston, P. G. (2006). c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25, 838–848.
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266, 807–810.
Lowe, S. W., Cepero, E., and Evan, G. (2004). Intrinsic tumour suppression. Nature 432, 307–315.
Lowe, S. W. and Lin, A. W. (2000). Apoptosis in cancer. Carcinogenesis 21, 485–495.
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481–490.
Luqmani, Y. A. (2005). Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14, 35–48.
Luu, Y., Bush, J., Cheung, K. J., Jr., and Li, G. (2002). The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res 276, 214–222.
Marchenko, N. D., Zaika, A., and Moll, U. M. (2000). Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275, 16202–16212.
Martelli, A. M., Tabellini, G., Bortul, R., Tazzari, P. L., Cappellini, A., Billi, A. M., and Cocco, L. (2005). Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol 20, 239–252.
McCormick, F. (2004). Cancer: survival pathways meet their end. Nature 428, 267–269.
McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., and Cotter, T. G. (1994). Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83, 1179–1187.
McManus, D. C., Lefebvre, C. A., Cherton-Horvat, G., St-Jean, M., Kandimalla, E. R., Agrawal, S., Morris, S. J., Durkin, J. P., and Lacasse, E. C. (2004). Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 23, 8105–8117.
Meek, D. W. (2004). The p53 response to DNA damage. DNA Repair (Amst) 3, 1049–1056.
Mendelsohn, J. and Fan, Z. (1997). Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89, 341–343.
Mesner, P. W., Jr., Budihardjo, II, and Kaufmann, S. H. (1997). Chemotherapy-induced apoptosis. Adv Pharmacol 41, 461–499.
Michalak, E., Villunger, A., Erlacher, M., and Strasser, A. (2005). Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun 331, 786–798.
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., and Moll, U. M. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11, 577–590.
Minucci, S. and Pelicci, P. G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38–51.
Miyashita, T. and Reed, J. C. (1992). bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52, 5407–5411.
Modur, V., Nagarajan, R., Evers, B. M., and Milbrandt, J. (2002). FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277, 47928–47937.
Morgensztern, D. and McLeod, H. L. (2005). PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16, 797–803.
Moroni, M. C., Hickman, E. S., Lazzerini Denchi, E., Caprara, G., Colli, E., Cecconi, F., Muller, H., and Helin, K. (2001). Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 3, 552–558.
Nagane, M., Levitzki, A., Gazit, A., Cavenee, W. K., and Huang, H. J. (1998). Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA95, 5724–5729.
Nahle, Z., Polakoff, J., Davuluri, R. V., McCurrach, M. E., Jacobson, M. D., Narita, M., Zhang, M. Q., Lazebnik, Y., Bar-Sagi, D., and Lowe, S. W. (2002). Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 4, 859–864.
Nakanishi, C. and Toi, M. (2005). Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5, 297–309.
Nelson, D. A. and White, E. (2004). Exploiting different ways to die. Genes Dev 18, 1223–1226.
Newmeyer, D. D. and Ferguson-Miller, S. (2003). Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112, 481–490.
Nguyen, D. M., Chen, G. A., Reddy, R., Tsai, W., Schrump, W. D., Cole, G., Jr., and Schrump, D. S. (2004). Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. J Thorac Cardiovasc Surg 127, 365–375.
Nicholson, K. M., Quinn, D. M., Kellett, G. L., and Warr, J. R. (2003). LY294002, an inhibitor of phosphatidylinositol-3-kinase, causes preferential induction of apoptosis in human multidrug resistant cells. Cancer Lett 190, 31–36.
Nieborowska-Skorska, M., Wasik, M. A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., and Skorski, T. (1999). Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 189, 1229–1242.
Notarbartolo, M., Cervello, M., Dusonchet, L., Cusimano, A., and D’Alessandro, N. (2002). Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 180, 91–101.
O’Gorman, D. M., McKenna, S. L., McGahon, A. J., Knox, K. A., and Cotter, T. G. (2000). Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 14, 602–611.
Okada, M., Adachi, S., Imai, T., Watanabe, K., Toyokuni, S. Y., Ueno, M., Zervos, A. S., Kroemer, G., and Nakahata, T. (2004). A novel mechanism for imatinib mesylate-induced cell death of Bcr-Abl-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 103, 2299–2307 (epub 2003 Nov 2226).
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (epub 2005 May 2015).
Orian, A., van Steensel, B., Delrow, J., Bussemaker, H. J., Li, L., Sawado, T., Williams, E., Loo, L. W., Cowley, S. M., Yost, C., et al. (2003). Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev 17, 1101–1114.
Orlowski, R. Z. and Baldwin, A. S., Jr. (2002). NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8, 385–389.
Osaki, M., Oshimura, M., and Ito, H. (2004). PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667–676.
Oster, S. K., Ho, C. S., Soucie, E. L., and Penn, L. Z. (2002). The myc oncogene: MarvelouslY Complex. Adv Cancer Res 84, 81–154.
Ozoren, N. and El-Deiry, W. S. (2002). Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4, 551–557.
Ozoren, N. and El-Deiry, W. S. (2003). Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 13, 135–147.
Page, C., Lin, H. J., Jin, Y., Castle, V. P., Nunez, G., Huang, M., and Lin, J. (2000). Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20, 407–416.
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., and Slamon, D. J. (1997). The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15, 537–547.
Pelengaris, S., Khan, M., and Evan, G. (2002). c-MYC: more than just a matter of life and death. Nat Rev Cancer 2, 764–776.
Perkins, C. L., Fang, G., Kim, C. N., and Bhalla, K. N. (2000). The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 60, 1645–1653.
Peter, M. E. and Krammer, P. H. (1998). Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 10, 545–551.
Peter, M. E. and Krammer, P. H. (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10, 26–35.
Pisha, E., Chai, H., Lee, I. S., Chagwedera, T. E., Farnsworth, N. R., Cordell, G. A., Beecher, C. W., Fong, H. H., Kinghorn, A. D., Brown, D. M., and et al. (1995). Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1, 1046–1051.
Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., and Kohn, K. W. (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23, 2934–2949.
Pompetti, F., Rizzo, P., Simon, R. M., Freidlin, B., Mew, D. J., Pass, H. I., Picci, P., Levine, A. S., and Carbone, M. (1996). Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 63, 37–50.
Proskuryakov, S. Y., Konoplyannikov, A. G., and Gabai, V. L. (2003). Necrosis: a specific form of programmed cell death? Exp Cell Res 283, 1–16.
Ravagnan, L., Roumier, T., and Kroemer, G. (2002). Mitochondria, the killer organelles and their weapons. J Cell Physiol 192, 131–137.
Ray, S., Lu, Y., Kaufmann, S. H., Gustafson, W. C., Karp, J. E., Boldogh, I., Fields, A. P., and Brasier, A. R. (2004). Genomic mechanisms of p210Bcr-Abl signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J Biol Chem 279, 35604–35615 (epub 32004 May 35621).
Reed, J. C. (1996). Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst Mitt, 72–100.
Reed, J. C. (2000). Mechanisms of apoptosis. Am J Pathol 157, 1415–1430.
Reinke, V. and Lozano, G. (1997). Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res 148, 115–122.
Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., and Baldwin, A. S., Jr. (1998). A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 12, 968–981.
Rokudai, S., Fujita, N., Kitahara, O., Nakamura, Y., and Tsuruo, T. (2002). Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol Cell Biol 22, 8695–8708.
Sakamuro, D., Eviner, V., Elliott, K. J., Showe, L., White, E., and Prendergast, G. C. (1995). c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene 11, 2411–2418.
Salvesen, G. S. and Dixit, V. M. (1997). Caspases: intracellular signaling by proteolysis. Cell 91, 443–446.
Salvesen, G. S. and Dixit, V. M. (1999). Caspase activation: the induced-proximity model. Proc Natl Acad Sci USA 96, 10964–10967.
Salvesen, G. S. and Renatus, M. (2002). Apoptosome: the seven-spoked death machine. Dev Cell 2, 256–257.
Sawyers, C. L., McLaughlin, J., and Witte, O. N. (1995). Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 181, 307–313.
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17, 1675–1687.
Scaffidi, C., Kirchhoff, S., Krammer, P. H., and Peter, M. E. (1999). Apoptosis signaling in lymphocytes. Curr Opin Immunol 11, 277–285.
Schimmer, A. D., Dalili, S., Batey, R. A., and Riedl, S. J. (2006). Targeting XIAP for the treatment of malignancy. Cell Death Differ 13, 179–188.
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., and Lowe, S. W. (1999). INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13, 2670–2677.
Schuler, M. and Green, D. R. (2005). Transcription, apoptosis and p53: catch-22. Trends Genet 21, 182–187.
Schulze-Bergkamen, H., and Krammer, P. H. (2004). Apoptosis in cancer–implications for therapy. Semin Oncol 31, 90–119.
Schulze-Osthoff, K., Ferrari, D., Los, M., Wesselborg, S., and Peter, M. E. (1998). Apoptosis signaling by death receptors. Eur J Biochem 254, 439–459.
Seelan, R. S., Irwin, M., van der Stoop, P., Qian, C., Kaelin, W. G., Jr., and Liu, W. (2002). The human p73 promoter: characterization and identification of functional E2F binding sites. Neoplasia 4, 195–203.
Sheikh, M. S. and Huang, Y. (2004). Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets 4, 97–104.
Shi, Y. (2002). Apoptosome: the cellular engine for the activation of caspase-9. Structure (Camb) 10, 285–288.
Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., and Sawyers, C. L. (1996). Constitutive activation of STAT5 by the Bcr-Abl oncogene in chronic myelogenous leukemia. Oncogene 13, 247–254.
Sillaber, C., Gesbert, F., Frank, D. A., Sattler, M., and Griffin, J. D. (2000). STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95, 2118–2125.
Skorski, T. (2002). BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 21, 8591–8604.
Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., et al. (1997). Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16, 6151–6161.
Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., et al. (2001). Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207–211.
Song, L., Coppola, D., Livingston, S., Cress, D., and Haura, E. B. (2005). Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 4, 267–276 (epub 2005 Mar 2020).
Sorice, M., Circella, A., Cristea, I. M., Garofalo, T., Renzo, L. D., Alessandri, C., Valesini, G., and Esposti, M. D. (2004). Cardiolipin and its metabolites move from mitochondria to other cellular membranes during death receptor-mediated apoptosis. Cell Death Differ 11, 1133–1145.
Stahl, M., Dijkers, P. F., Kops, G. J., Lens, S. M., Coffer, P. J., Burgering, B. M., and Medema, R. H. (2002). The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168, 5024–5031.
Stegh, A. H. and Peter, M. E. (2001). Apoptosis and caspases. Cardiol Clin 19, 13–29.
Stiewe, T. and Putzer, B. M. (2000). Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26, 464–469.
Strasser, A., Harris, A. W., Bath, M. L., and Cory, S. (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331–333.
Strasser, A., O’Connor, L., and Dixit, V. M. (2000). Apoptosis signaling. Annu Rev Biochem 69, 217–245.
Suhara, T., Kim, H. S., Kirshenbaum, L. A., and Walsh, K. (2002). Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Molecular and Cellular Biology 22, 680–691.
Sunters, A., Fernandez de Mattos, S., Stahl, M., Brosens, J. J., Zoumpoulidou, G., Saunders, C. A., Coffer, P. J., Medema, R. H., Coombes, R. C., and Lam, E. W. (2003). FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278, 49795–49805 (epub 42003 Oct 49793).
Tai, Y. T., Lee, S., Niloff, E., Weisman, C., Strobel, T., and Cannistra, S. A. (1998). BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16, 2583–2590.
Teitz, T., Lahti, J. M., and Kidd, V. J. (2001). Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med 79, 428–436.
Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., and Kidd, V. J. (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6, 529–535.
Thompson, C. B. (1995). Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456–1462.
Thorburn, A. (2004). Death receptor-induced cell killing. Cell Signal 16, 139–144.
Tomita, Y., Marchenko, N., Erster, S., Nemajerova, A., Dehner, A., Klein, C., Pan, H., Kessler, H., Pancoska, P., and Moll, U. M. (2006). WTp53 but not tumor-derived mutants bind to BCL2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 26, 26.
Toretsky, J. A., Thakar, M., Eskenazi, A. E., and Frantz, C. N. (1999). Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing’s sarcoma family of tumors. Cancer Res 59, 5745–5750.
Tourneur, L., Delluc, S., Levy, V., Valensi, F., Radford-Weiss, I., Legrand, O., Vargaftig, J., Boix, C., Macintyre, E. A., Varet, B., et al. (2004). Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res 64, 8101–8108.
Tzung, S. P., Kim, K. M., Basanez, G., Giedt, C. D., Simon, J., Zimmerberg, J., Zhang, K. Y., and Hockenbery, D. M. (2001). Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3, 183–191.
Underhill-Day, N., Pierce, A., Thompson, S. E., Xenaki, D., Whetton, A. D., and Owen-Lynch, P. J. (2006). Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance. Br J Haematol 132, 774–783.
Varticovski, L., Daley, G. Q., Jackson, P., Baltimore, D., and Cantley, L. C. (1991). Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 11, 1107–1113.
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (epub 2004 Jan 2002).
Vaux, D. L. (2002). Apoptosis timeline. Cell Death Differ 9, 349–354.
Vaux, D. L. and Korsmeyer, S. J. (1999). Cell death in development. Cell 96, 245–254.
Vogelstein, B., Lane, D., and Levine, A. J. (2000). Surfing the p53 network. Nature 408, 307–310.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature medicine 5, 157–163.
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., and Korsmeyer, S. J. (2004). Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466–1470.
Wallach, D. (1997). Apoptosis. Placing death under control. Nature 388, 123, 125–126.
Wallach, D., Varfolomeev, E. E., Malinin, N. L., Goltsev, Y. V., Kovalenko, A. V., and Boldin, M. P. (1999). Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17, 331–367.
Walton, M. I., Whysong, D., O’Connor, P. M., Hockenbery, D., Korsmeyer, S. J., and Kohn, K. W. (1993). Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53, 1853–1861.
Wang, G. Q., Gastman, B. R., Wieckowski, E., Goldstein, L. A., Gambotto, A., Kim, T. H., Fang, B., Rabinovitz, A., Yin, X. M., and Rabinowich, H. (2001). A role for mitochondrial Bak in apoptotic response to anticancer drugs. J Biol Chem 276, 34307–34317 (epub 32001 July 34310).
Wang, J. L., Liu, D., Zhang, Z. J., Shan, S., Han, X., Srinivasula, S. M., Croce, C. M., Alnemri, E. S., and Huang, Z. (2000). Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97, 7124–7129.
Wang, J. Y. and Ki, S. W. (2001). Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73. Biochem Soc Trans 29, 666–673.
Wang, L. G., Liu, X. M., Kreis, W., and Budman, D. R. (1999). The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44, 355–361.
Wang, W. and El-Deiry, W. S. (2004). Targeting FOXO kills two birds with one stone. Chem Biol 11, 16–18.
Waxman, D. J. and Schwartz, P. S. (2003). Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 63, 8563–8572.
Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. J. (2001a). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730.
Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. J. (2001b). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730.
Weller, M. (1998). Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 292, 435–445.
Wendel, H. G., De Stanchina, E., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., and Lowe, S. W. (2004). Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332–337.
Wennerberg, K., Rossman, K. L., and Der, C. J. (2005). The Ras superfamily at a glance. J Cell Sci 118, 843–846.
Whitesell, L. and Lindquist, S. L. (2005). HSP90 and the chaperoning of cancer. Nat Rev Cancer 5, 761–772.
Xu, H., Tai, J., Ye, H., Kang, C. B., and Yoon, H. S. (2006). The N-terminal domain of tumor suppressor p53 is involved in the molecular interaction with the anti-apoptotic protein Bcl-Xl. Biochem Biophys Res Commun 341, 938–944 (epub 2006 Jan 2023).
Yagita, H., Takeda, K., Hayakawa, Y., Smyth, M. J., and Okumura, K. (2004). TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95, 777–783.
Yang, X., Chang, H. Y., and Baltimore, D. (1998). Autoproteolytic activation of pro-caspases by oligomerization. Mol Cell 1, 319–325.
Yin, H., Lee, G. I., Sedey, K. A., Kutzki, O., Park, H. S., Orner, B. P., Ernst, J. T., Wang, H. G., Sebti, S. M., and Hamilton, A. D. (2005). Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. J Am Chem Soc 127, 10191–10196.
Yoo, C. B. and Jones, P. A. (2006). Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5, 37–50.
Yu, J. and Zhang, L. (2005). The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331, 851–858.
Yuan, X. J. and Whang, Y. E. (2002). PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21, 319–327.
Zaffaroni, N., Pennati, M., Colella, G., Perego, P., Supino, R., Gatti, L., Pilotti, S., Zunino, F., and Daidone, M. G. (2002). Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59, 1406–1412.
Zamzami, N. and Kroemer, G. (2001). The mitochondrion in apoptosis: how Pandora’s box opens. Nat Rev Mol Cell Biol 2, 67–71.
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., and Vogelstein, B. (2000). Role of BAX in the apoptotic response to anticancer agents. Science 290, 989–992.
Zhou, P., Qian, L., Kozopas, K. M., and Craig, R. W. (1997). Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89, 630–643.
Zinkel, S. S., Ong, C. C., Ferguson, D. O., Iwasaki, H., Akashi, K., Bronson, R. T., Kutok, J. L., Alt, F. W., and Korsmeyer, S. J. (2003). Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev 17, 229–239.
Zong, W. X., Ditsworth, D., Bauer, D. E., Wang, Z. Q., and Thompson, C. B. (2004). Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18, 1272–1282 (epub 2004 May 1214).
Zornig, M., Hueber, A., Baum, W., and Evan, G. (2001). Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551, F1–F37.
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media B.V
About this chapter
Cite this chapter
Melet, A., Song, K., Bucur, O., Jagani, Z., Grassian, A.R., Khosravi-Far, R. (2008). Apoptotic Pathways in Tumor Progression and Therapy. In: Programmed Cell Death in Cancer Progression and Therapy. Advances in Experimental Medicine and Biology, vol 615. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6554-5_4
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6554-5_4
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6553-8
Online ISBN: 978-1-4020-6554-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)